Medical Doctor Program year 2021 Reported 2020–2021 Source: CMS Open Payments, 2026 publication

Jerry Waters

Pain Medicine Oroville, CA Medical Doctor

NPI 1528075454 CMS profile 23295

2767 Olive Hwy, Ste 9, Oroville, CA 95966

Open in the dashboard

General payments

$48

2 records reported · program years 2020–2021

Research payments

$0

Paid to them · None reported · program years 2020–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Jerry Waters of Oroville, CA is reported in the CMS Open Payments database as having received $48 across 2 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 6th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $24 1
2020 General $24 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jerry Waters
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Jerry Waters were reported at $0. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Jerry Waters Pain Medicine median Middle half National median
2019 $0 $506 $144–$1,566 $163
2020 $24 $315 $96–$934 $114
2021 $24 $452 $134–$1,237 $132
2022 $0 $475 $124–$1,407 $149
2023 $0 $480 $136–$1,384 $160
2024 $0 $521 $164–$1,511 $164
2025 $0 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2020–2021
  1. Merck Sharp & Dohme Corporation $48 2 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2021
  1. Food and Beverage $48 2 payments
Products named General payments · program years 2020–2021
  1. BRIDION $24 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 72 drugs

Part D claims

2,911

Median for Pain Management: 951

Drug cost

$98,100

Median for Pain Management: $26,034

Branded share of claims

9.9%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 28 $25,235
Ozempic Semaglutide Brand 23 $21,503
Januvia Sitagliptin Phosphate Brand 11 $15,798
Levothyroxine Sodium Generic 250 $2,491
Valsartan Generic 87 $2,387
Ventolin Hfa Albuterol Sulfate Brand 26 $2,217
Wixela Inhub Fluticasone Propion/Salmeterol Brand 32 $2,065
Gabapentin Generic 75 $1,837
Synthroid Levothyroxine Sodium Brand 24 $1,791
Tamsulosin Hcl Generic 93 $1,581

The 10 drugs with the highest cost, of 72 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Records

2 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record